On Sunday, Britain government reported having secured two million doses of Moderna Inc’s COVID-19 vaccine candidate. This is to be available at the earliest spring in Europe. Additionally, 5 million doses have been already obtained from the US company two weeks ago. The news followed a day after Prime Minister Boris Johnson held Nadhim Zahawi, a junior business minister, responsible for the deployment of COVID-19 vaccines.
At present, the country has access to enough doses of Moderna’s vaccine candidate for around 3.5 million people. In total, 357 million doses of vaccines are available from seven developers, as notified by the government. “With a wide range of vaccine candidates in our portfolio, we stand ready to deploy a vaccine should they receive approval from our medicines regulator, starting with those who will benefit most,” Health Minister Matt Hancock stated.
Based on the interim data from a late-stage trial, Moderna’s experimental vaccine is 94.5 percent effective in preventing COVID-19. If the vaccine meets all the standards of the Medicines and Healthcare products Regulatory agency, it will be delivered as early as the spring. As of now, Britain has ordered 40 million doses of a vaccine developed by Germany’s BioNTech SE and Pfizer Inc of the United States. These are 95 percent effective in preventing the spread of the Coronavirus.
On Saturday, as per the report by a media agency, the UK regulator is set to approve the BioNTech-Pfizer vaccine by this week and deliveries will begin within the hours of authorisation. Britain has successfully secured 100 million doses of the vaccine developed by AstraZeneca PLC and Oxford University and has targeted distribution before Christmas.